 we are participating in the session of the 42nd annual conference of the _ abbvie _ group of investors.    
 we will start with a look into the future of the company, and then we will move on to some of the topics that are of interest to investors.    
 we start with a look into the future of some of the key growth drivers for the company.   
 we will start with the migraine franchise, which has important growth implications for AbbVie.  
 we will then move on to some of the other CNS franchises, which are an important growth pillar for the company.    
 finally, we will move on to some of the topics of interest to investors.   
 we will start with some of the topics of interest to investors, and then we will move to some of the topics of interest to them.    
 we will then move to some of the topics of interest to investors, including some of the topics of interest to them, and we will finish with some of the topics of interest to them, including some of the topics of interest to investors, but we will conclude with some additional questions.    
 we